This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1
NHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot study of the technology, according to chief executive Sir Simon Stevens. “We are determined to see UK-wide availability of life-changing type 1 diabetes technology options on the NHS,” she added.
This company specializes in biopharmaceuticals, diabetes care, obesity care, and other severe chronic diseases. The partnership aims to redesign healthcare professionals’ access and use of critical information about diabetes care. Interested in building your own Digital Content Factory? Let us know!
Additionally, she holds the title of Certified Diabetes Care and Education Specialist (CDCES). Overcoming Barriers Despite the challenges in her current role, including communication barriers due to the diverse linguistic landscape of her clinic, Dr. Gutierrez-Miller remains dedicated to providing the best care possible.
In our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he hopes to bring the NHS and pharma together to improve outcomes in diabetes and other long-term conditions. Collaborating to prevent diabetes. How can we get that message into communities? Digital tools.
On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D). Tzield’s approval brings the opportunity to explore how the drug can advance diabetes education, treatment, and management. “We Equity in early-stage testing.
After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. Tighter glucose control is known to reduce the risk of complications of diabetes like cardiovascular disease and nerve damage affecting the eyes and extremities.
Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). A Phase I/II study of VCTX211 has been commenced and is currently ongoing. It originated under the partnership of CRISPR Therapeutics and ViaCyte.
According to the letter, the agency noted first of all that the video that was part of the Instagram post stated that Trulicity could “lower A1C along with diet and exercise” but that the Medication Guide specifically states that the drug is used for people with type 2 diabetes. So why did OPDP act upon this Instagram post?
In recognition of American Diabetes Month , the growing need for effective, accessible and patient-centered diabetes care is emphasized. Approximately 38 million Americans live with diabetes, a condition requiring multiple medications, lifestyle adjustments and frequent monitoring to prevent serious complications. As the U.S.
US healthcare group Carbon Health has made a move into digital care for patients with chronic conditions, buying diabetes-focused startup Steady Health. ” The post Carbon Health buys virtual diabetes clinic firm Steady Health appeared first on.
Imagine this as a patient when you are under extreme duress and walk into a clinic or hospital; clear communication is often not feasible. Compelling and well-enunciated communications are quite rare between patient and doctor. Importance of Quality Patient-Doctor Communication.
At Novo Nordisk, we are dedicated to tackling chronic diseases by driving change in diabetes, obesity, rare diseases- haemophilia, growth hormone deficiency, etc., Simplifying diabetes care, awareness around obesity and related complications, CVDs and rare diseases like haemophilia continue to be the focus areas for the Indian market.
The most common etiology of CN III palsy is ischemia of the nerve fibers secondary to diabetes mellitus or hypertension, which preferentially affects the internal somatic fibers that surround the blood supply. However, the most feared etiology is an intracranial aneurysm, most commonly a posterior communicating artery aneurysm.
At least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), mainly Africa, are set to benefit from Eli Lilly and Company and manufacturer EVA Pharmaceutical’s new collaboration delivering a sustainable supply of high-quality, affordable human and analogue insulin to this population.
Recent data from the Japan Diabetes Clinical Data Management (JDDM) study suggests that average HbA1c levels – a biomarker for blood glucose control – have been creeping up among diabetics, indicating that insulin isn’t being used as effectively as it could be. “Patients are receiving an average of 14.8
New Trusted Messengers Campaign Tackles Heart Disease, Diabetes and Obesity February 6, 2025 By: Leah Poffenberger, Senior Manager, Communications Millions of Americans are impacted by heart disease, diabetes, or obesityoften in tandem.
Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression. Excellent Communication Skill. Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai, India. Job Profile: . Female Medical Representatives. Company : Cipla.
Originally developed for people with type 2 diabetes like Fernandez’s parents, Wegovy — the brand name for one of an expanding class of injectable medicines known as GLP-1 receptor agonists — was helping people lose up to 15% of their body weight. They weren’t, originally, even designed to get into the brain.
Previously-developed automated insulin delivery systems can be a useful tool for type 1 diabetics, however they can be incredibly expensive for the patient, making this technology inaccessible for most who therefore have to rely on manually injecting themselves with their daily insulin doses. read more.
The NHS will soon be offering an artificial pancreas to more than 100,000 people with type 1 diabetes across England and Wales. It is hoped the device will help them manage their condition more effectively, improving quality of life and reducing risk of long-term health issues. read more.
US-based biotech company Creative Medical Technology has announced that it has filed for the FDA’s Orphan Drug Designation (ODD) for its treatment for Brittle Type 1 diabetes. read more
Pharmaceutical company Merck has announced that it is attempting to reduce levels of a cancer-causing compound which has been found in its popular type 2 diabetes drugs. The compound, known as nitrosamines or NTTP, often emerges from chemical reactions that can take place throughout the manufacturing process. read more
Asked how he made the shift from working out the structure of proteins and how molecules bind to those proteins, to the founding of pharmaphorum and focusing on the digital space, his answer was clear: communication. Tunnah realised, in fact, that that communicative passion lay within himself and wasn’t satisfied by academic work.
In an industry as specialized as healthcare, personalized communication can make or break your relationship with HCPs and patients. Here’s a quick look at a successful email campaign in pharma: Objective : Increase awareness about a new diabetes drug. That’s the power of healthcare email marketing.
Japan-based Sosei Heptares announced that it has joined forces with UK global biopharma company Eli Lilly to discover, develop and commercialise small molecules which modulate novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases. read more.
The drug is already approved in the EU for the treatment of type 2 diabetes as well as chronic kidney disease. AstraZeneca has announced that its drug, Forxiga, has been approved in the EU for the treatment of symptomatic chronic heart failure. This follows an approval from the EMA’s Committee for Medicinal Products for Human Use in December.
.” “Efforts to expand access to medicines, especially insulin, are only beneficial when effective cold chain systems are in place to keep them at the right temperature on their way to patients,” commented Leigh Ann Pusey, Executive Vice President of corporate affairs and communications for Lilly.
It also improves care coordination and eliminates communication gaps. It involves the training of community paramedics in performing some aspects of medication reconciliation. Any medication changes found during these reviews are communicated to the PCP and community pharmacist. What led you to this career path?
We need as many different layers of communication as we can get to make self-care viable in the future”. Hudson stresses the importance of good communications from pharma and healthcare to improve literacy and trust – but says that the industry still often lacks the ability to truly connect with its customers. Ed Hudson, Create Health.
The latest development comes after Lilly and Sosei Heptares signed a partnership for developing small molecules that modulate new G protein-coupled receptor targets linked to diabetes and metabolic diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Patient Communication Some call it creating “happy patients,” others want to improve “patient experience,” and yet others mention “patient satisfaction.” Regardless of the term you use, communicating with patients in order to improve their care, compliance, and satisfaction is a worthy goal. It’s a matter of good health. “My
Abbott has joined forces with two other companies to bring an automated insulin delivery (AID) system to people with diabetes in Europe that will monitor blood glucose levels and deliver insulin automatically. Adding Abbott to the alliance closes the circle, moving close to an entirely automated system for people with diabetes.
The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.
First results of the DiabetRisk study – Over 8% of patients identified with undiagnosed diabetes or pre-diabetes at dental practices. The DiabetRisk study could contribute to early diagnosis of diabetes in thousands of dental patients each year – and in every country worldwide.
The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.
This can lead to metabolic abnormalities including insulin resistance, diabetes, and elevated levels of blood lipids (such as high cholesterol). Partial lipodystrophy results in a partial loss, but the fat that remains is redistributed in inappropriate places around the body. Fighting for access.
Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time. Smart insulin pens are expected to drive the insulin pen market from $13.8
Just like coronavirus, other diseases have a higher incidence in some locations than others – for example diabetes is far more prevalent in Alabama than it is Colorado. If you were marketing a diabetes drug, would you use the same marketing plan in Colorado as you would in Alabama?
(World Diabetes Day, 14 November 2021). The collaborative research with Shiga University of Medical Science and Sunstar also proves that diabetes and smoking impact tooth retention. The collaborative research with Shiga University of Medical Science and Sunstar also proves that diabetes and smoking impact tooth retention.
Pharmacy Performance Metrics Medication Adherence: Non-adherence to three chronic disease categories — oral diabetes medications, statins for cholesterol, and hypertension medications — impacts a pharmacy’s adherence score. To comply, pharmacies need to coordinate with doctors to get statins prescribed to patients with diabetes.
Approved Indications of Trulicity2 Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients (age: ≥10 years) with type 2 diabetes mellitus. million patients’ journeys with type 2 diabetes since 2014.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content